Pozen criticises partner AZ as it vows to make aspirin/PPI combo affordable
This article was originally published in Scrip
Executive Summary
Pozen continues its search for a partner for its GI-friendly aspirin candidate, PA32540, and believes that, if approved, the sequential release formulation could be aimed at a wide target population, Pozen chief executive Dr John Plachetka told Scrip. But it doesn't want to go down the high-price-low-volume route that an existing partner, AstraZeneca, took another of Pozen's combination drugs, Vimovo.